Genetic and Molecular Markers in Glioblastoma:: Α systematic review
Aristotle University of Thessaloniki · 01.01.2026
DOI: 10.26262/heal.auth.ir.373985 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Aristotle University of Thessaloniki, erschienen am 01.01.2026. Verfasst von Ξανθούλα Γ. Λαμπριανού.
Abstract (Originalsprache)
Background
Glioblastoma is the most aggressive primary brain tumor in adults, characterized by intense molecular heterogeneity and limited therapeutic response. Although numerous genetic and molecular biomarkers have been proposed to support diagnosis, prognosis, and treatment selection, only a subset has been systematically evaluated. This thesis synthesizes and evaluates evidence from existing literature to determine the prognostic and predictive value of genetic and molecular biomarkers in adult glioblastoma.
Methods
A systematic review was conducted according to the PRISMA 2020 guidelines. PubMed, Scopus and Google Scholar were searched for studies reporting molecular or genetic biomarkers in histologically or molecularly confirmed adult glioblastoma.
Results
Ten studies met the inclusion criteria. MGMT promoter methylation demonstrated consistent and high-quality evidence supporting its prognostic and predictive significance, particularly in relation to response to temozolomide. Other classical biomarkers such as IDH1/2 mutations, TERT promoter mutations, EGFR/EGFRvIII amplification and TP53, have shown variable and often inconsistent prognostic relevance, in part due to methodological heterogeneity and changes in diagnostic criteria introduced by the 2021 WHO classification. Chromosomal alterations such as +7/–10 have been found to be diagnostically informative but have no substantial prognostic value. Emerging biomarkers, including microRNAs, circulating tumor DNA, and radiogenomic signatures, have shown promising potential for diagnosis and monitoring of glioblastoma, but remain limited by small sample sizes, inconsistent methodologies, and inadequate validation.
Conclusion
MGMT promoter methylation is the only biomarker with robust, clinical utility in glioblastoma. Emerging technologies offer future prospects but require rigorous validation before clinical integration. Advancing biomarker-based precision medicine in glioblastoma will depend on standardized methodologies, prospective multicentre studies, and the development of polyomic integrative approaches.
Schlagwörter
Zitieren
APA
Λαμπριανού, Ξ. Γ. (2026). Genetic and Molecular Markers in Glioblastoma:: Α systematic review. Aristotle University of Thessaloniki. https://doi.org/10.26262/heal.auth.ir.373985
Vancouver
Λαμπριανού ΞΓ. Genetic and Molecular Markers in Glioblastoma:: Α systematic review. Aristotle University of Thessaloniki. 2026. doi:10.26262/heal.auth.ir.373985
BibTeX
@article{2026,
author = {Λαμπριανού, Ξανθούλα Γ.},
title = {Genetic and Molecular Markers in Glioblastoma:: Α systematic review},
journal = {Aristotle University of Thessaloniki},
year = {2026},
doi = {10.26262/heal.auth.ir.373985}
}
EUVIMED